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ABSTRACT
Objective: The goal of this research was to evaluate antihyperuricemic activity of Stelechocarpus burahol leaves subfractions and isolate its chemical 
constituent of active subfraction.
Methods: Ethyl acetate fraction from S. burahol extract was subfractionated by vacuum liquid chromatography, and the active subfractions were 
further subfractionated by classic column chromatography using isocratic eluent, followed by isolated chemical constituent from active subfraction. 
Hyperuricemic rat model was induced by given potassium oxonate intraperitoneally. The inhibitory effect of subfractions on the xanthine oxidase (XO) 
activity was determined using ultraviolet-visible spectrophotometry method.
Results: Subfractions E.3, E.4, and E.5 significantly (p<0.05) reduced the serum uric acid (UA) level 43%, 46%, and 33%, respectively. The E.3, E.4, and E.5 
have showed very weak XO inhibitory activity. Subfraction E.3.2 and E.4.3 significantly (p<0.05) reduced the serum UA level 29% and 38%, respectively, 
however still very weak effect on XO activity. Chemical constituent which was isolated from subfraction E.4.3 was kaempferol-3-O-rhamnoside.
Conclusion: The subfractions of ethyl acetate fraction had antihyperuricemic activity in vivo but less effect on XO activity in vitro. Isolated compound 
in active antihyperuricemic of subfraction E.4.3 was kaempferol-3-O-rhamnoside.
Keywords: Stelechocarpus burahol, Subfraction, Antihyperuricemic, Xanthine oxidase inhibitory activity, Kaempferol-3-O-rhamnoside.
INTRODUCTION
Hyperuricemia means high levels of uric acid (UA) in the blood, a 
condition considered to be closely associated with increasing risks 
for developing gout, cardiovascular diseases, hypertension, and 
metabolic syndrome [1,2]. The risk of developing gout is closely related 
to the serum UA level. The 5-year risk of gout varied from 0.6% for 
those with a serum UA level >7 mg/dl to 30.5% for those with a level 
>10 mg/dl [3]. UA is the end-product of purine metabolism in human 
with the loss uricase. Xanthine oxidase (XO) converts hypoxanthine 
to xanthine and xanthine to UA [4]. The XO activity derived species 
reactive oxygen species/reactive nitrogen species (ROS/RNS). ROS and 
RNS can generate ischemic-reperfusion (IR) injury [5].
Currently available antihyperuricemic agents for chronic gout can 
be classified into three categories: (i) uricostatic (XO inhibitor), for 
example, allopurinol and febuxostat, (ii) uricosuric, for example, 
benzbromarone, sulfinpyrazone, and probenecid, and (iii) uricolytic, 
for example, uricozyme and rasburicase [6,7]. Despite advances in 
the use of antihyperuricemic agents for hyperuricemia and gout 
treatment, however, adverse effects such as severe hypersensitivity 
reactions associated with allopurinol and severe hepatotoxicity risk of 
benzbromarone limit their therapy usage [8].
The medicinal use of botanical plants is gaining renewed interest in 
connection with the sustaining of health and clinical disorder. Scientists 
have studied to explore the potent antihyperuricemic from a wide 
variety of traditional herbal plants. Many plants have potential as 
medicinal plants for gout treatment [9]. Stelechocarpus burahol (Bl.) 
is a traditionally plant for antihyperuricemic and gout [10]. The trees 
are widely distributed in Thailand, Vietnam, Malaysia, Indonesia (Java, 
Bali, Sumatra, and Borneo) [11]. The local name in Indonesia is burahol, 
turalak (Sunda) or kepel (Jawa) [12]. A previous study revealed that 
ethanolic extract from S. burahol leaves was one of the samples which 
had a potent antihyperuricemic in vivo compared to Annona squamosa, 
Annona muricata, and Annona reticulata [13]. N-hexane and ethyl 
acetate fractions of S. burahol leaves decreased serum UA level in 
rats [14]. Furthermore, the S. burahol leaves contained flavonoid and 
terpenoid [10,15]. Many researchers reported that some of flavonoid 
compounds have strong XO inhibitory and antihyperuricemic in vivo 
activity. However, it is not clear which compounds are active in the 
extract, fraction and subfraction. This study aimed to evaluate the 
potent of subfractions of S. burahol in lowering of UA. The activity was 
evaluated by in vivo potassium-oxonate-induced acute hyperuricemia 
and in vitro XO inhibitory activity assay. Furthermore, phytochemical 
compound of active subfraction was isolated and identified.
METHODS
Materials
Xanthine, XO, potassium dihydrogen phosphate, dimethyl 
sulfoxide (DMSO), potassium oxonate were purchased from Sigma 
Chemicals Co. Allopurinol was obtained from Ifars Pharmaceutical 
Laboratories. The UA kit was purchased from Sclavo Diagnostic. 
Silica gel 60 H for thin-layer chromatography and silica gel 60 
(0.063 – 0.200 mm) for column chromatography from Merck were used.
Instrument and reagent
Nuclear magnetic resonance (NMR) spectra (1H-NMR and13C-NMR 
spectra taken at 500 MHz and 125 Hz of Agilent 500 MHz by Consol 
Sistem) were recorded in deuterated solvent using methanol. MS 
spectra were measured using ultra-performance liquid chromatography 
quadrupole time-of-flight mass spectrometry/mass spectrometry 
(Waters) ESI positive with mobile phase A (H2O, 0.1% formic acid) and 
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B (acetonitrile, 0.1% formic acid), gradient method. Ultraviolet (UV) 
spectra were identified using spectrodensitometry (Camag Thin-layer 
Chromatography Scanner).
Animal
Male Wistar rats weighed 170-200 g (age, 7-8 weeks) were obtained 
from the animal laboratory (School of Pharmacy, Bandung Institute of 
Technology). The rats were allowed to adapt to their environment at a 
constant temperature of 25°C for a week before being used. They were 
given free access to feed standard pellets and water during the study. All 
the procedures were approved by Animal Ethics Committee, Bandung 
Institute of Technology.
Plant materials
Leaves of S. burahol was collected from Central Java, Indonesia, and 
determined in School of Life Science and Technology, Bandung Institute 
of Technology. The materials were washed, wet sortation, dried, and 
grinded into powder.
Preparation of the extract and fractionation
The dried leaves powder of S. burahol (6 kg) was macerated with 30 L 
ethanol 96% for 5 days at room temperature. After 5 days, the mixture 
was filtered and the residue washed using ethanol and treated for 
5 days of the same treatment as before. The extract was concentrated 
under reduced pressure to yield a residue (9.2%). The ethanolic extract 
was then suspended with Aquadest and extracted successively with 
equal volume of n-hexane and ethyl acetate. Each fraction was then 
concentrated under reduced pressure to obtain n-hexane fraction 
(33%), ethyl acetate fraction (12%), and aqueous fraction (32%). 
The ethyl acetate fraction was subfractionated by vacuum liquid 
chromatography. The column was packed with silica gel H and then 
eluted by mobile phase that was fifty eluent system n-hexane, ethyl 
acetate, and methanol, with increasing polarity (10:0:0→0:0:1 v/v), to 
divide the fraction into seven subfractions (E.1-E.7). Each subfraction 
E.3 (1.0 g) and E.4 (0.7 g) was then subfractionated by classical 
column chromatography by isocratic elution using chloroform-
methanol (8:2) to give three and four subfractions (E.3.1-E.3.3 and 
E.4.1-E.4.4). Subfraction E.4.3 (184 mg) was purified by preparative 
paper chromatography with mobile phase acetic acid 10% to give three 
subfractions (E.4.3.1-E.4.3.3). Subfraction E.4.3.2 was then purified by 
preparative thin layer chromatography with mobile phase chloroform-
methanol (8:2) to obtain compound R (5.7 mg).
In vivo antihyperuricemic activity
Animal model and drug administration
Before being used in the experiment, the rats fasted 1 day. The 
animals were carried to the laboratory at least 1 hr before the 
experiment begins. Water was withdrawn from the animals 1 hr 
before drug administration. The experiment was conducted using 
modified Liu’s method [16]. Rats were divided randomly into 
normal control, hyperuricemic control, standard (allopurinol), and 
sample groups (n=6 each). Potassium oxonate, subfractions, and 
allopurinol were dispersed in 0.3% carboxymethylcellulose sodium. 
The dose of subfraction was calculated from percentage of yielding 
subfraction. The subfractions were given orally to rats. Allopurinol 
(10 mg/kg) was used as standard. The volume of the suspension which 
was administered based on body weight of rat. Before potassium 
oxonate administration, whole blood was collected for determining 
serum UA level on 0 h. Briefly, 1 h before the drug administration, 
all rats were injected intraperitoneally with potassium oxonate 
250 mg/kg to increase the serum UA level, except normal control 
group. Whole blood samples were collected from rats by tail vein 
bleeding in duration 1st h to 3rd h for obtaining UA level on 1st, 2nd, and 
3rd h after drug administration.
UA assay
The blood was allowed to clot for 30 minutes at room temperature and 
then centrifuged at 10.000 × g for 7 minutes to obtain the serum. Serum 
was stored at −20°C until assayed. Serum UA level was determined by 
enzymatic colorimetric method using a standard diagnostic kit.
In vitro XO inhibitory activity
XO inhibitory activity was performed based on Umamaheswari [17] and 
Abdullahi [18] with minor modification. 1 ml fraction (25-200 µg/ml) 
was mixed 0.9 ml phosphate buffer 50 mM (pH 7.5 at 25°C) and 0.1 ml 
XO enzyme solution (0.1 unit/ml in phosphate buffer, pH 7.5) and pre-
incubated on for 15 minutes at 25°C. 2 ml of xanthine solution 0.15 mM 
(prepared fresh) was added to the mixture and then incubated for 
30 minutes at 25°C. The reaction was then stopped by adding 1 ml 1N 
hydrochloric acid, and the absorbance was measured at λ 287 nm using 
UV-Vis spectrophotometer. Different concentrations of the fraction 
(25-200 µg/ml) were dissolved in DMSO. Allopurinol (0.2-1.6 µg/ml) 
was used as the positive control. All of the experiments were conducted 
in triplicate. The XO inhibitory activity of fraction was assessed as the 
inhibitory percentage (%):
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where A is the activity of the enzyme without the extract, B is the 
control of A without the extract and enzyme, and C and D are the 
activity of the extract with and without XO, respectively. The assay was 
done in triplicate, and IC50 values were calculated from the percentage 
of inhibition 50%.
Statistical analysis
Results showed and represent the mean±standard deviation. The 
significant difference was statistically calculated by the analysis of 
variance (one-way), followed by Tukey’s post-hoc test. Statistical 
significant was set at p<0.1, 0.05, and 0.01.
RESULTS AND DISCUSSION
Antihyperuricemic activity of subfractions E.1-E.7
The antihyperuricemic activity of subfractions E.1-E.7 on hyperuricemic 
rats using potassium oxonate is shown in Table 1. In the present study, 
potassium oxonate, a well-known uricase inhibitor, was used to induce 
hyperuricemia in rats [19]. The serum UA level of chemically induced 
hyperuricemic rats was significantly higher (p<0.01) than normal 
control, which indicated that hyperuricemic rat model has been 
successfully established. Treatment by subfractions E.1-E.7 can reduce 
serum UA level of hyperuricemic rats, and only E.3 (43%), E.4 (46%), and 
E.5 (33%) showed significantly different compared to hyperuricemic 
control (p<0.05). The dose of subfraction was calculated using response 
profile of ethyl acetate fraction and percentage of yielding subfractions. 
This was assumed that subfractions which obtained from bioactivity-
guided subfractionation will contain more bioactive constituents than 
the crude ethanol extract or ethyl acetate fraction and thus will show 
inhibition higher than the crude drugs of ethanol extract [13] and ethyl 
acetate fraction [14].
The XO inhibitory activity of subfractions E.1-E.7 was evaluated by 
the xanthine-XO enzymatic system. The influence of subfraction on 
XO activity was calculated by decreasing production of UA, which was 
measured by UV-Vis spectrophotometry. The XO inhibitory activity of 
subfractions which were resulted from subfractionation of ethyl acetate 
fraction by vacuum liquid chromatography is presented in Table 2. 
Those subfractions E.1-E.7 expressed low and no effect on XO inhibitory 
activity. Subfractions E.1-E.6 elicited a dose-dependent inhibition of XO 
enzyme activity. At concentration of 200 g/ml, the highest activity was 
given by E.3 subfraction, followed by E.4 and E.2 subfractions. These 
results were compared to allopurinol, which revealed 48.69±1.82% 
inhibition at 2 µg/ml concentration (Table 1). The all of subfractions had 
IC50 more than 200 µg/ml, which were categorized as very weak activity.
Antihyperuricemic activity of subfractions E.3.1-E.4.4
The antihyperuricemic activity of subfractions E.3.1-E.4.4, which were 
resulted from subfractionation of subfractions E.3 and E.4, is given in Table 3. 
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In the present study, the serum UA level of hyperuricemic group increased 
more than 1.5-fold compared to normal control. The rat which was induced 
by potassium oxonate can serve as a useful hyperuricemia animal model 
to evaluate serum UA levels of sample. The oral treatment by subfractions 
E.3.1-E.4.4 could reduce serum UA level of hyperuricemic rats compared to 
hyperuricemic control; however, only E.3.2 (20 mg/kg), E.4.2 (8 mg/kg), 
and E.4.3 (8 mg/kg) subfractions demonstrated antihyperuricemic activity 
(p<0.05). The rats were treated by subfraction E.4.3 had UA levels that 
were significantly reduced 38% followed by E.3.2 29% compared to 
hyperuricemic group (p<0.01). On the other hand, serum UA level of 
hyperuricemic group and the rats which were treated by subfractions 
E.3.1, E.3.3, E.4.1, and E. 4.4 were not significantly different.
All subfractions of E.3 and E.4 presented a dose-dependent inhibition 
of XO enzyme activity. The results demonstrated that subfractions 
E.3.1-E.4.4 possessed XO inhibitory activity as shown in Table 4. Among 
the obtained subfractions, the subfraction E.3.2 at concentration of 
200 µg/ml, the highest activity was given by E.3.2 (63.79%), followed 
E.4.4 (43.20%) and E.4.3 (41.46%). The subfraction E.3.2 gave XO 
inhibitory activity with IC50 128.39±20.21 µg/ml, while the other 
subfractions which were resulted by classical column chromatography 
of E.3 and E.4 gave IC50 more than 200 ug/ml. The XO inhibitory activity of 
subfractions E.3.1-E.4.4 was compared to allopurinol, which is clinically 
used as a drug for the XO inhibitor [20]. Allopurinol as standard showed 
very strong inhibitory activity with IC50 1.08±0.04 µg/ml (Table 4).
The subfractions E.3.1-E.4.4 which were resulted from subfractionation 
of E.3 and E.4 subfractions by classical column chromatography had 
antihyperuricemic activity in vivo but had less XO inhibitory activity 
in vitro. The previous studies also found that ethanolic extract of 
S. burahol exposed lower XO inhibitory activity but had significant 
antihyperuricemic activity in vivo [14,21].
Table 1: UA level of hyperuricemic rats before and after giving subfractions (E.1-E.7)
Group Dose (mg/kg) Serum UA level (mg/dl)
0 h 1 h 2 h 3 h
Normal 2.62±0.33 2.42±0.37r 2.34±0.28r 2.46±0.39r
Hyperuricemic 2.53±0.19 3.61±0.21cz 3.92±0.22cz 3.86±0.17cz
Allopurinol 10 2.46±0.36 1.82±0.40r 1.93±0.16r 2.20±0.51r
E.1 35 2.67±0.26 3.05±0.40z 3.46±0.15cpz 3.54±0.20bz
E.2 14 2.37±0.49 2.59±0.25pz 3.14±0.20cz 3.16±0.46cz
E.3 8 2.49±0.39 2.07±0.14r 2.72±0.13bqz 3.00±0.67az
E.4 8 2.42±0.14 1.94±0.82r 2.72±0.61bqz 2.89±0.60y
E.5 8 2.40±0.59 2.42±0.43rz 3.37±0.35bz 2.93±0.78x
E.6 7 2.21±0.38 2.60±0.21pz 2.96±0.56cz 2.77±0.40y
E.7 10 2.30±0.40 2.70±0.64az 3.18±0.37cz 2.83±0.40ax
ap<0.1; bp<0.05; cp<0.01 compared to normal control. pp<0.1; qp<0.05; rp<0.01 compared to hyperuricemic control. xp<0.1; yp<0.05; zp<0.01 compared to allopurinol. 
UA: Uric acid
Table 2: In vitro xanthine oxidase inhibitory activity of subfractions (E.1-E.7)
Group Percentage of xanthine oxidase inhibition (µg/ml) IC50 (µg/ml)
25 50 100 200
E.1 2.93±2.5 6.56±3.47 7.50±2.67 10.10±1.87 >200
E.2 7.90±2.20 12.55±3.96 13.83±4.57 18.22±7.78 >200
E.3 13.00±3.50 21.36±4.01 28.22±3.61 42.02±4.05 >200
E.4 3.46±2.06 8.38±5.91 13.82±3.84 19.84±4.90 >200
E.5 2.82±2.78 4.53±2.36 4.88±2.93 9.10±3.70 >200
E.6 6.70±1.82 6.35±2.40 6.95±2.99 9.27±3.51 >200
E.7 12.08±7.08 5.55±7.76 −5.84±2.78 3.47±22.50 -
Allopurinol Percentage of xanthine oxidase inhibition (µg/ml) 2.16±0.53
0.2 0.5 1 2
10.62±1.39 16.73±2.97 27.69±7.95 48.69±10.82
-: No activity
Table 3: UA level of hyperuricemic rats before and after giving subfractions (E.3.1-E.4.4)
Group Dose (mg/kg) Serum UA level (mg/dl)
0 hr 1 hr 2 hr 3 hr
Normal 2.62±0.33 2.42±0.37r 2.34±0.28q 2.46±0.39r
Hyperuricemic 2.80±0.43 3.61±0.32cz 4.43±0.68cx 4.16±0.95cz
Allopurinol 10 2.46±0.36 1.82±0.40qx 1.93±0.16q 2.20±0.51r
E.3.1 12 2.83±0.24 2.99±0.45z 3.79±0.65cz 3.78±0.68y
E.3.2 20 2.87±0.28 2.55±0.32ary 3.37±0.18pz 3.56±0.89y
E.3.3 5 2.72±0.65 2.99±0.37z 3.97±0.48cz 3.89±0.57bz
E.4.1 12 2.98±0.14 2.96±0.42z 3.74±0.72cz 4.04±0.92bz
E.4.2 8 2.82±0.28 2.80±0.45qz 3.75±0.84cz 4.08±0.60cz
E.4.3 8 2.57±0.40 2.23±0.38r 3.53±0.48bz 3.72±0.63y
E.4.4 6 2.76±0.30 2.93±0.26pz 4.13±0.51bz 4.08±0.75cz
UA: Uric acid. Keterangan: ap<0.1; bp<0.05; cp<0.01 compared to normal control. pp<0.1; qp<0.05; rp<0.01 compared to hyperuricemic control. xp<0.1; yp<0.05; zp<0.01 
compared to allopurinol
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Structure elucidation
The subfraction E.4.3 of S. burahol leaves was purified by preparative 
paper chromatography and repurified by preparative thin layer 
chromatography. Compound R was obtained as a pale yellow amorphous 
powder. The UV spectrum of R showed λmax at 268 nm and 348 nm 
which was suggested as flavonoid [22]. Table 5 revealed the chemical 
shift value of1H and13C-NMR for compound R. The 1H and 13C-NMR 
values of all carbons were assigned on the basic of heteronuclear 
single quantum coherence (HSQC) and heteronuclear multiple bond 
correlation (HMBC).
Based on the characterization and identification by UV-visible 
spectrophotodensitometry, 1H-NMR, 13C-NMR, HSQC, and HMBC 
demonstrated that isolate was predicted as kaempferol-3-O-
rhamnoside (C21H20O10). It was also confirmed by mass spectrum which 
presented molecular ion [M+H+] at 433.38, while the molecular weight 
of kaempferol-3-O-rhamnoside (C21H20O10) is 432.38 g/mol. Therefore, 
it can be concluded that isolate was kaempferol-3-O-rhamnoside 
(Fig. 1).
The isolate of active subfraction, kaempferol-3-O-rhamnoside, may 
be active compound. The structure–activity relationships exhibited 
that flavones and flavonols with a-7-hydroxyl group such as chrysin, 
luteolin, kaempferol, quercetin, myricetin, and isorhamnetin inhibited 
XO activity at low concentration. The previous research presented that 
kaempferol showed XO inhibitory activity at IC50 value 0.67 µM [23]. 
Ahmad [24] denoted that kaempferol had XO inhibitory activity at 
IC50 1.87 μg/ml whereas the IC50 of kaempferol-3-O-ß-D-glucopyranoside 
and kaempferol-3-O-(4-O-galloyl)-α-L-arabinopyranoside was 11.74 
and 13.96 µg/ml, respectively. The main inhibition mechanism of 
Table 4: In vitro xanthine oxidase inhibitory activity of subfractions (E.3.1-E.4.4)
Group Percentage of xanthine oxidase inhibition (µg/ml) IC50 (µg/ml)
25 50 100 200
E.3.1 15.91±2.69 18.68±2.42 30.01±6.04 33.22±4.17 >200
E.3.2 26.93±2.42 34.86±2.34 46.70±2.24 63.79±4.28 128.39±20.21
E.3.3 15.88±1.88 22.51±6.69 25.44±4.16 28.67±1.84 >200
E.4.1 5.98±2.87 13.54±5.31 15.72±6.89 15.47±7.07 >200
E.4.2 7.29±6.53 6.65±4.60 11.09±5.99 19.60±5.56 >200
E.4.3 22.35±4.53 25.33±6.22 32.14±3.93 41.46±7.19 >200
E.4.4 17.59±4.21 22.38±6.95 31.38±3.50 43.20±9.03 >200
Allopurinol Percentage of xanthine oxidase inhibition (µg/ml) 1.08±0.04
0.2 0.5 1 2
21.93±4.67 35.28±6.80 47.66±3.38 78.02±2.93
Table 5: 1H and 13C-NMR chemical shift value for compound R





6 6.20 (1H, d, 2.1 Hz) 99.95 C-6 C-8, C-9, C-10
7 - 166.24




2’, 6’ 7.77 (2H, d, 8.5 Hz) 131.88 H-2’↔C-2’ C-4’, C-6’, C-2
H-6’↔C-6’ C-4’, C-2’, C-2
3’, 5’ 6.94 (2H, d, 8.5 Hz) 116.54 H-3’↔C-3’ C-4’, C-5’, C-1’
H-5’↔C-5’ C-4’, C-3’, C-1’
4’ - 159.26
Ar-OH 4.2 - - -
1” 5.37 (1H, s) 103.49 C-1” C-4, C-3, C-3”, C-5”
2” 3.72 (1H, m) 72.04 C-2’
3” 3.71 (1H, m) 73.17 C-3”
4” 3.68 (1H, m) -
5” 3.65 (1H, m) 71.91 C-5”
6”(CH3) 0.95 (3H, d, 4.5 Hz) 17.65 C-6” C-5”, C-4”
HSQC: Heteronuclear single quantum coherence, HMBC: Heteronuclear multiple bond correlation, NMR: Nuclear magnetic resonance
Fig. 1: Heteronuclear single quantum coherence and 
heteronuclear multiple bond correlation of compound R
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kaempferol on XO activity may be due to the insertion of kaempferol 
into the active site of XO occupied the catalytic center of the enzyme 
to avoid the entrance of the substrate and induced conformational 
changes of XO [25]. Kaempferol is presented antihyperuricemic activity 
in mice hyperuricemic [26].
CONCLUSION
The subfractions of ethyl acetate fraction which were resulted 
from subfractionation by a vacuum liquid chromatography and 
further subfractionation by a classical column chromatography had 
antihyperuricemic activity in vivo but gave less XO inhibitory activity 
in vitro. Compound R in active antihyperuricemic subfraction E.4.3 was 
kaempferol-3-O-rhamnoside.
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